Medication-assisted treatment (MAT) for opioid use disorder is the most evidence-based intervention available — reducing overdose deaths by up to 50%, improving treatment retention, and reducing criminal activity associated with active addiction. Yet fewer than 25% of people with opioid use disorder receive any form of MAT. A major barrier is confusion about which medication is appropriate and what the differences actually mean day-to-day. Here's a plain-language clinical comparison.

Quick Comparison: All Three MAT Options

Buprenorphine (Suboxone): How It Works

Buprenorphine is a partial opioid agonist — it activates opioid receptors, but only partially, creating a ceiling on its euphoric and respiratory depressant effects. This ceiling effect is what makes it significantly safer in overdose than full agonists like methadone or heroin. Even at very high doses, buprenorphine does not suppress breathing the way full agonists do.

Suboxone combines buprenorphine with naloxone in a 4:1 ratio. The naloxone component is poorly absorbed sublingually but becomes active if the tablet is injected — precipitating immediate withdrawal and deterring injection misuse. Sublocade is a once-monthly injectable buprenorphine that removes the burden of daily dosing and eliminates diversion risk entirely.

Since 2023, the X-waiver (DATA 2000 waiver) requirement has been eliminated — any DEA-registered provider can now prescribe buprenorphine for OUD without special training or patient caps. This has significantly expanded access, particularly in rural areas and primary care settings where OTP clinics are not available.

Methadone: How It Works

Methadone is a full opioid agonist with a long half-life of 24–36 hours, providing stable blood levels that eliminate cravings and block the euphoric effects of other opioids. For opioid use disorder, methadone can only be dispensed through federally certified Opioid Treatment Programs (OTPs) — not through regular prescribers.

Patients typically begin with daily observed dosing at the clinic. As they demonstrate compliance — clean urine drug screens, consistent attendance, engagement with counseling — they earn "take-home" doses, up to 27 days' supply for stable long-term patients under current federal guidelines. This structure provides accountability and daily contact with treatment staff, which some patients find beneficial. For others — particularly those with jobs, children, or transportation barriers — daily clinic attendance is a major obstacle to treatment.

Naltrexone (Vivitrol): The Third Option

Naltrexone is an opioid antagonist — it completely blocks opioid receptors rather than activating them. It produces no euphoria, has no abuse potential, and requires no special prescribing certification. Monthly injectable Vivitrol maintains consistent blood levels and removes the adherence challenges of daily oral naltrexone tablets.

The critical limitation is that naltrexone requires complete opioid detoxification before initiation — typically 7–10 days opioid-free for short-acting opioids, longer for methadone. Any opioids in the system when naltrexone is given will cause immediate precipitated withdrawal. This detox requirement means naltrexone is best suited for patients who have already completed residential detox or who are highly motivated and have strong support systems.

A key safety concern: if a patient stops naltrexone and relapses, their opioid tolerance has been reset to zero. Using the same dose they used before starting naltrexone can cause a fatal overdose. Patients and families need to understand this risk before starting and after any missed doses.

Effectiveness: What the Research Shows

Both buprenorphine and methadone dramatically outperform no medication or placebo. A landmark 2020 Cochrane review — the gold standard for evidence synthesis — found both significantly reduce illicit opioid use, improve treatment retention, and reduce mortality compared to no medication or placebo. Key findings:

• Both reduce overdose mortality by approximately 50% compared to no MAT
• Methadone shows slightly higher treatment retention in most direct head-to-head comparisons
• Buprenorphine shows comparable efficacy with a meaningfully better safety profile
• Extended-release naltrexone (Vivitrol) shows similar efficacy to buprenorphine among patients who successfully complete detox and initiation — but the detox requirement creates a significant real-world completion gap
• A landmark X:BOT trial (Lee et al., 2018 NEJM) found that once successfully initiated, extended-release naltrexone and buprenorphine had similar 24-week outcomes — but 28% of naltrexone patients failed to initiate due to detox barriers versus 6% of buprenorphine patients

Who Is the Right Candidate for Each?

Buprenorphine (Suboxone) May Be Preferable If:

• You want to take medication at home without daily clinic visits
• You have work, school, or family obligations incompatible with daily clinic attendance
• You are pregnant (buprenorphine is preferred in pregnancy — see below)
• You have lower to moderate opioid tolerance
• You live in an area without accessible OTP clinics
• You have no prior buprenorphine treatment failures

Methadone May Be Preferable If:

• You have very high opioid tolerance — particularly from high-dose fentanyl or heroin
• Buprenorphine has not worked adequately in prior treatment attempts
• You benefit from or need the structure of daily clinic attendance and monitoring
• An OTP clinic is accessible from where you live
• You do not have contraindications such as significant cardiac issues or problematic drug interactions

Naltrexone (Vivitrol) May Be Preferable If:

• You have already completed a full medical detox and are opioid-free
• You are highly motivated and have strong social support
• You have professional or legal reasons to avoid any opioid-based medication
• You have already relapsed on buprenorphine or methadone
• You prefer a monthly injection to daily medication

MAT in Pregnancy

For pregnant women with opioid use disorder, MAT is strongly recommended over medically supervised withdrawal. Untreated opioid use disorder during pregnancy carries serious risks including preterm labor, fetal distress, and neonatal death. Buprenorphine is the preferred medication for pregnant patients — it is associated with lower rates of neonatal opioid withdrawal syndrome (NOWS) compared to methadone, and unlike methadone, does not require daily clinic attendance.

Naltrexone is not recommended during pregnancy due to insufficient safety data. Methadone remains an option for women already stable on methadone — abrupt switching is not recommended. Both buprenorphine and methadone are compatible with breastfeeding in small amounts.

Cost and Insurance Coverage

Under MHPAEA and the ACA, most insurance plans — including Medicaid and Medicare — cover all three MAT medications. Coverage typically falls under both medical benefits (prescribing visits) and pharmacy benefits (medications). Some plans require prior authorization.

• Buprenorphine (Suboxone): Generic buprenorphine is widely available — often $10–$40/month at most pharmacies with insurance. Sublocade (monthly injection) is typically covered under medical benefits with prior auth. GoodRx and SAMHSA programs provide assistance for uninsured patients.
• Methadone (OTP): Typically $300–$500/month without insurance for daily dosing. Most Medicaid plans cover OTP methadone at minimal or no cost. Medicare Part B now covers OTP services including methadone.
• Naltrexone (Vivitrol): The monthly injection lists at approximately $1,900 without insurance. Most commercial insurance and Medicaid plans cover it. The manufacturer (Alkermes) has a patient assistance program for uninsured patients.

Our specialists verify your specific MAT benefits — buprenorphine, methadone, and Vivitrol — as part of every free insurance check. Call (844) 561-0606 to find out exactly what your plan covers.

Related Articles